Devices and technology in the news

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

The use of the Cambridge hybrid closed-loop insulin delivery system by older adults with type 1 diabetes mellitus is associated with “improved quality of life,” says an international team of researchers.

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

Use of intermittently scanned continuous glucose monitoring is associated with an increased likelihood for treatment intensification in people with type 2 diabetes, a study shows.

A short period of intermittently scanned continuous glucose monitoring prior to a first endocrinologist consultation can improve glycemic outcomes for people with type 2 diabetes, report the SPOT FIRST study researchers.

People with high diabetes distress achieve reductions in glycated hemoglobin and the need for emergency care for acute diabetes complications after starting on intermittently scanned continuous glucose monitoring, report researchers.

The benefits of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes are sustained for at least 2 years, shows the extension of the ALERTT1 study.

Fully subsidizing continuous glucose monitors could overcome disparities in their use by people with diabetes, suggests research conducted in adults enrolled in a US Medicaid program.

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.

Findings from a randomized controlled trial published in Diabetes Care suggest that for people with type 2 diabetes, the delivery of cognitive behavioral therapy via a digital therapeutic app, on top of standard of care, may reduce glycated hemoglobin.

Brief, repeated use of real-time continuous glucose monitoring may help to improve glycemic control in people with type 2 diabetes who would otherwise need to escalate to insulin, suggests a small randomized trial.

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

The improved glycemic control gained from use of intermittently scanned continuous glucose monitoring is sustained for at least 2 years in people with type 1 diabetes, show real-world data.

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Gaining the use of a low blood glucose alert by switching from the FreeStyle Libre 1 to 2 reduces the amount of time people with type 1 diabetes spend in hypoglycemia, report researchers.

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.